Evidence map›Paper›PMID 36429392›Full record

ArticleInternational journal of environmental research and public health2022

Long COVID at Different Altitudes: A Countrywide Epidemiological Analysis.

Juan S Izquierdo-Condoy, Raul Fernandez-Naranjo, Eduardo Vasconez-González, Simone Cordovez, Andrea Tello-De-la-Torre, Clara Paz, Karen Delgado-Moreira, Sarah Carrington, Ginés Viscor, Esteban Ortiz-Prado

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Juan S Izquierdo-CondoyOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito 170137, Ecuador.ORCID 0000-0002-1178-0546
Raul Fernandez-NaranjoOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito 170137, Ecuador.ORCID 0000-0002-4875-9652
Eduardo Vasconez-GonzálezOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito 170137, Ecuador.ORCID 0000-0003-4573-6217
Simone CordovezOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito 170137, Ecuador.
Andrea Tello-De-la-TorreOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito 170137, Ecuador.
Clara PazOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito 170137, Ecuador.ORCID 0000-0003-1106-9567
Karen Delgado-MoreiraOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito 170137, Ecuador.
Sarah CarringtonLugar, Medio y Sociedad Research Group, School of Economics, Universidad de Las Américas, Quito 170124, Ecuador.
Ginés ViscorDepartament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0003-4942-2346
Esteban Ortiz-PradoOne Health Research Group, Faculty of Health Science, Universidad de Las Americas, Quito 170137, Ecuador.ORCID 0000-0002-1895-7498
Universidad de Las Américas · ECUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral reports from around the world have reported that some patients who have recovered from COVID-19 have experienced a range of persistent or new clinical symptoms after a SARS-CoV-2 infection. These symptoms can last from weeks to months, impacting everyday functioning to a significant number of patients.

methodsA cross-sectional analysis based on an online, self-reporting questionnaire was conducted in Ecuador from April to July 2022. Participants were invited by social media, radio, and TV to voluntarily participate in our study. A total of 2103 surveys were included in this study. We compared socio-demographic variables and long-term persisting symptoms at low (<2500 m) and high altitude (>2500 m).

resultsOverall, 1100 (52.3%) responders claimed to have Long-COVID symptoms after SARS-CoV-2 infection. Most of these were reported by women (64.0%); the most affected group was young adults between 21 to 40 years (68.5%), and most long-haulers were mestizos (91.6%). We found that high altitude residents were more likely to report persisting symptoms (71.7%) versus those living at lower altitudes (29.3%). The most common symptoms were fatigue or tiredness (8.4%), hair loss (5.1%) and difficulty concentrating (5.0%). The highest proportion of symptoms was observed in the group that received less than 2 doses.

conclusionsThis is the first study describing post-COVID symptoms' persistence in low and high-altitude residents. Our findings demonstrate that women, especially those aging between 21-40, are more likely to describe Long-COVID. We also found that living at a high altitude was associated with higher reports of mood changes, tachycardia, decreased libido, insomnia, and palpitations compared to lowlanders. Finally, we found a greater risk to report Long-COVID symptoms among women, those with previous comorbidities and those who had a severer acute SARS-CoV-2 infection.

Indexed as

AltitudeCOVID-19Cross-Sectional StudiesFemaleHumansPost-Acute COVID-19 SyndromeSARS-CoV-2Young AdultCOVID-19high altitudeLatin Americalong-COVIDSARS-CoV-2sequalaesymptoms

Identifiers

PMID36429392
PMCPMC9690364
OpenAlexW4308720765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.